Can you manage FM without opioids? Study of 698 Fibromyalgia pts from a tertiary center finds 27.1% taking opioids. Opioid associated with longer Sx duration (>3 yrs), increased age, worse functional impairment & pain catastrophizing https://t.co/N1G4ZtkUE5

• https://bit.ly/37xtM8k

Delays in Joint Replacement as JIA Patients Reach Adulthood https://t.co/EQNZPD8d7o The JIA category, year of implant, and presence of complications significantly affected implant survivorship. https://t.co/yiD74AElPC

• https://bit.ly/3CrUTQN

FDA issued Drug Safety Communication to statin manufacturers requesting they remove strong warnings against statin use during pregnancy. While statins appear in breast milk, they should not be contraindicated, if needed, during Pregnancy https://t.co/AeFwpsLMXT

• https://bit.ly/3ivUG77

Pfizer has another JAK inhibitor - ritlecitinib - shown to be effective (vs PBO) in alopecia areata in the Phase 2b/3 ALLEGRO trial. Ritlecitinib is also being studied in vitiligo, rheumatoid arthritis, Crohn’s & ulcerative colitis. https://t.co/ccx0eRXuTS https://t.co/fApTP7WaYU

• https://bit.ly/3jxDCwN

IL-6 Inhibitor Safety Issues-Download now! https://t.co/rjId76sJ64 https://t.co/QwBJNmrzBf

• https://bit.ly/3rTYbay

In a head to head trial Upadacitinib was superior to Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis. 24wk DBRCT, 924 pts given either UPA 30/d vsDUP 300 EOW. ESI75 response@wk16, UPA 71% vs DUP 61% https://t.co/5cOoosKyao

• https://bit.ly/3CsmgtO

New podcast available for download! https://t.co/5K8ejJ4jj2 https://t.co/Va66dLGrXO

• https://bit.ly/3ClyxQJ

ICYMI: Skin Involvement with HMGCR Necrotizing Myositis The Journal of Autoimmunity reports that anti-HMRCR antibody positive, necrotizing myositis patients frequently have cutaneous lesions, more so than previously reported. https://t.co/RR07dYIJSr https://t.co/MiaIqvMPaB

• https://bit.ly/3ClniaX

ICYMI: D-penicillamine Adverse events reported to FDA (1970-2020): dystonia (OR 20.52), drug hypersensitivity (OR 5.42), pancytopenia (OR 10.2), joint swelling (OR 9.07), Renal (OR 6.68), dysphagia (OR 5.05), CHF (OR 4.04), edema (OR: 3.77) https://t.co/8lmYiJo2Tz

• https://bit.ly/3Ag2vE1

ICYMI: CRESS – A New Composite Measure for Primary Sjögren's Syndrome https://t.co/7tvjBvP3g4

• https://bit.ly/3yu9lFy

ICYMI: JRheum review: 40–50% of psoriasis pts have psoriatic nail disease NP). NP is an important predictor of enthesitis, which is associated with the early stages of PsA https://t.co/sEuih3CSgX

• https://bit.ly/3zYCNn6

It was a banner week at the FDA; a new drug approval you should know about; a lot of information about pregnancy & safety; and an interesting case plus a question from one of our readers submitted. This and more in this week's podcast. Let's dive in. https://t.co/5K8ejJ4jj2 https://t.co/pqCsvYuI96

• https://bit.ly/3ClyxQJ

Veterans study gout prevalence rose from 4.2% to 5.8%, 2005 to 2014. 2014, 4.0% of all inpatient/outpatient encounters & 1.3% of hospitalizations were gout related. ULT use remained stable with 46% of gout patients receiving ULT https://t.co/Lmf2mmMddW

• https://bit.ly/2Vrnq8g

Skin Involvement with HMGCR Necrotizing Myositis The Journal of Autoimmunity reports that anti-HMRCR antibody positive, necrotizing myositis patients frequently have cutaneous lesions, more so than previously reported. https://t.co/RR07dYIJSr https://t.co/f4WdkRZWpM

• https://bit.ly/3ClniaX